AbbVie Q3 2026 Earnings: 100% EPS Growth, Raised Guidance & Dividend Hike
AbbVie’s Q3 2026 earnings beat expectations, with double‑digit growth from Skyrizi and Rinvoq driving a 100 % EPS jump. The company raised its full‑year guidance and dividend, signaling robust immunology momentum despite a Humira decline.
3 minutes to read